Yersinia rLcrV and rYopB inhibits the activation of murine peritoneal macrophages in vitro.
Yersinia antigenic proteins LcrV and YopB are translocators of effector Yops in type III secretion system. Recently, we have reported that rLcrV and rYopB inhibit the production of TNF-alpha, IFN-gamma, and IL-12 in murine peritoneal macrophages. It was also demonstrated that IL-10 and TLR2 signaling pathways and inhibition of MAPK cascade is involved in rLcrV- and rYopB-induced immunomodulation. In the present study, it is reported that rLcrV and rYopB inhibited the LPS-induced production of IL-1beta in macrophages. Pretreatment of macrophages with rLcrV and rYopB also inhibited the LPS-induced transcription of IL-6 but not of GM-CSF. However, the transcription of chemokines like MCP-1, MIP-1alpha, MIP-1beta, and RANTES were inhibited by rLcrV and rYopB. Both proteins also affected the cytoskeleton and lipid rafts in macrophages. It is further observed that IL-10 antibodies abrogated the rLcrV- and rYopB-induced inhibition of IL-1beta production in LPS-treated macrophages. The data, therefore, suggests a possible role of IL-10 in rLcrV and rYopB mediated inhibition of LPS-induced production of IL-1beta in macrophages.
Sodhi
Ajit
A
School of Biotechnology, Banaras Hindu University, Varanasi, UP, India. ajit.sodhi@lycos.com
Sharma
Rajesh Kumar
RK
Batra
H V
HV
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000494:pharmacology*; D001425:Bacterial Outer Membrane Proteins / Q000494:pharmacology*; D002478:Cells, Cultured; D018925:Chemokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D016753:Interleukin-10 / Q000276:immunology; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D008262:Macrophage Activation / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008297:Male; D021962:Membrane Microdomains / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D052899:Pore Forming Cytotoxic Proteins; D015007:Yersinia / Q000276:immunology* / Q000378:metabolism*; D000093242:Interleukin-6 Inhibitors
D000906:Antibodies; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D018925:Chemokines; D007375:Interleukin-1; D016753:Interleukin-10; D015850:Interleukin-6; D008070:Lipopolysaccharides; D052899:Pore Forming Cytotoxic Proteins; D000093242:Interleukin-6 Inhibitors; C043908:LcrV protein, Yersinia; C078909:YopB protein, Yersinia